Is it time to reconsider combination lipid therapy in high-risk diabetic patients?

dc.contributor.author	Blood, Alexander J
dc.contributor.author	Krasuski, Richard A
dc.coverage.spatial	England
dc.date.accessioned	2016-08-01T13:41:58Z
dc.date.issued	2016-06
dc.identifier	http://www.ncbi.nlm.nih.gov/pubmed/27145105
dc.identifier	00041433-201660000-00017
dc.identifier.eissn	1473-6535
dc.identifier.uri	https://hdl.handle.net/10161/12515
dc.language	eng
dc.publisher	Ovid Technologies (Wolters Kluwer Health)
dc.relation.ispartof	Curr Opin Lipidol
dc.relation.isversionof	10.1097/MOL.0000000000000306
dc.title	Is it time to reconsider combination lipid therapy in high-risk diabetic patients?
dc.type	Journal article
duke.contributor.orcid	Krasuski, Richard A\|0000-0003-3150-5215
pubs.author-url	http://www.ncbi.nlm.nih.gov/pubmed/27145105
pubs.begin-page	310
pubs.end-page	311
pubs.issue	3
pubs.organisational-group	Clinical Science Departments
pubs.organisational-group	Duke
pubs.organisational-group	Medicine
pubs.organisational-group	Medicine, Cardiology
pubs.organisational-group	School of Medicine
pubs.publication-status	Published
pubs.volume	27

Files

Now showing 1 - 1 of 1